Pre-made Daxdilimab biosimilar ( Whole mAb, anti-LILRA4 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-135
Anti-LILRA4 therapeutic antibody (Pre-made Daxdilimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Daxdilimab is a novel drug designed to target and bind to ILT7, which is a cell surface molecule specific to the pDC type of dendritic cells. It is currently being investigated against autoimmune diseases and COVID-19. and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-LILRA4 therapeutic antibody (Pre-made Daxdilimab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Cutaneous lupus erythematosus;Dermatomyositis;Polymyositis;Sjogren's syndrome;Systemic lupus erythematosus;Systemic scleroderma;Acute lung injury|